MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

During remission, new symptoms typically resolve or improve. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective ...

However, benign MS may change to a progressive form of MS. Multiple sclerosis (MS) can vary greatly from person to person. Benign MS is a term sometimes used to describe a form of MS in which a ...

Many people who receive an initial diagnosis of relapsing-remitting MS gradually worsen over time, separate from ...

Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) Tolebrutinib is the first and only brain-penetrant ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

We also look forward to evaluating BRIUMVI in other indications outside of MS, and enrolling patients with progressive MS ...